Heparin resistance in acute coronary syndromes

Journal of Thrombosis and Thrombolysis

Volumn 23, Issue 2, 2007, Pages 93-100

  Rich, Jonathan D ^a   Maraganore, John M ^b   Young, Edward ^c   Lidon, Rosa Maria ^d   Adelman, Burt ^b   Bourdon, Paul ^b   Charenkavanich, Supoat ^b   Hirsh, Jack ^c   Theroux, Pierre ^d   Cannon, Christopher P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BIOGEN   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Anticoagulation; Heparin; Resistance

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; HEPARIN; HIRULOG; NITRIC ACID DERIVATIVE; THROMBOCYTE FACTOR 4;

ACUTE CORONARY SYNDROME; ADULT; ANTICOAGULATION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOSE RESPONSE; DRUG PROTEIN BINDING; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SMOKING HABIT; THORAX PAIN; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA, UNSTABLE; ANTICOAGULANTS; CASE-CONTROL STUDIES; CORONARY ARTERIOSCLEROSIS; DRUG RESISTANCE; FEMALE; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PARTIAL THROMBOPLASTIN TIME; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS;

EID: 33947233304     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-006-9049-9     Document Type: Article

References (34)

1. Hirsh J (1991) Heparin. The New England J Med 324(22):1565-1574
2. Young E, Prins M, Levine MN, Hirsh J (1992) Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemostasis 67(6):639-643
3. Warkentin TE, Greinacher A (2004) Heparin-induced thrombocytopenia: recognition, treatment, and prevention: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3 suppl):311S-337S
4. Horne MK 3rd, Hutchison KJ (1998) Simultaneous binding of heparin and platelet factor-4 to platelets: Further insights into the mechanism of heparin-induced thrombocytopenia. Am J Hematol 58(1):24-30
5. Young E, Wells P, Holloway S, Weitz J, Hirsh J (1994) Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thrombosis Haemostasis 71(3):300-304
6. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, Lopez-Sendon JL, Guneri S, Jiang F, White HD, Fox KA, Braunwald E (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. The New England J Med 354(14):1477-1488
7. Antman EM (1996) Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation 94(5):911-921
8. Cannon CP, Maraganore JM, Loscalzo J, McAllister A, Eddings K, George D, Selwyn AP, Adelman B, Fox I, Braunwald E et al (1993) Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol 71(10):778-782
9. Ferguson JJ (1995) Recent advances in the treatment of acute myocardial infarction. Texas Heart Inst J/Texas Heart Inst St 22(1):26-32
10. Fox I, Dawson A, Loynds P, Eisner J, Findlen K, Levin E, Hanson D, Mant T, Wagner J, Maraganore J (1993) Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemostasis 69(2):157-163
11. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW 2nd (1990) Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29(30):7095-7101
12. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The global use of strategies to open occluded coronary arteries (GUSTO) IIb investigators. The New England J Med 335(11):775-782 (1996)
13. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. The New England J Med 354(14):1464-1476
14. Hirsh J, Levine MN (1992) Low molecular weight heparin. Blood 79(1):1-17
15. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. The New England J Med 332(20):1330-1335
16. Di Nisio M, Middeldorp S, Buller HR (2005) Direct thrombin inhibitors. The New England J Med 353(10):1028-1040
17. Young E, Podor TJ, Venner T, Hirsh J (1997) Induction of the acute-phase reaction increases heparin-binding proteins in plasma. Arteriosclerosis Thromb Vascular Biol 17(8):1568-1574
18. Casu B, Oreste P, Torri G, Zoppetti G, Choay J, Lormeau JC, Petitou M, Sinay P (1981) The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies. Biochem J 197(3):599-609
19. Teien AN, Lie M (1977) Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 10(3):399-410
20. Rosenberg RD (1989) Biochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism. Am J Med 87(3B):2S-9S
21. Hirsh J, Anand SS, Halperin JL, Fuster V (2001) Guide to anticoagulant theAapy: Heparin: a statement for healthcare professionals from the American Heart Association. Circulation 103(24):2994-3018
22. McGarry TF Jr, Gottlieb RS, Morganroth J, Zelenkofske SL, Kasparian H, Duca PR, Lester RM, Kreulen TH (1992) The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J 123(6):1445-1451
23. Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, Anderson D, Johnson M (1994) A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Int Med 154(1):49-56
24. Becker RC, Ball SP, Eisenberg P, Borzak S, Held AC, Spencer F, Voyce SJ, Jesse R, Hendel R, Ma Y, Hurley T, Hebert J (1999) A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Antithrombotic Therapy Consortium Investigators. Am Heart J 137(1):59-71
25. Hochman JS, Wali AU, Gavrila D, Sim MJ, Malhotra S, Palazzo AM, De La Fuente B (1999) A new regimen for heparin use in acute coronary syndromes. Am Heart J 138(2 Pt 1):313-318
26. Kroon C, ten Hove WR, de Boer A, Kroon JM, van der Pol JM, Harthoorn-Lasthuizen EJ, Schoemaker HC, van der Meer FJ, Cohen AF (1992) Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers. Circulation 86(5):1370-1375
27. Olson ST, Shore JD (1982) Demonstration of a two-step reaction mechanism for inhibition of alpha-thrombin by antithrombin III and identification of the step affected by heparin. J Biol Chem 257(24):14891-14895
28. Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U (1984) Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 218(3):725-732
29. Cloyd GM, D'Ambra MN, Akins CW (1987) Diminished anticoagulant response to heparin in patients undergoing coronary artery bypass grafting. The J Thoracic Cardiovas Surgery 94(4):535-538
30. Esposito RA, Culliford AT, Colvin SB, Thomas SJ, Lackner H, Spencer FC (1983) Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment. The J Thoracic Cardiovas Surgery 85(3):346-353
31. Staples MH, Dunton RF, Karlson KJ, Leonardi HK, Berger RL (1994) Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping. The Ann Thoracic Surgery 57(5):1211-1216
32. Gilchrist IC, Berkowitz SD, Thompson TD, Califf RM, Granger CB (2002) Heparin dosing and outcome in acute coronary syndromes: The GUSTO-IIb experience. Global use of strategies to open occluded coronary arteries. Am Heart J 144(1):73-80
33. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation 97(24):2386-2395 (1998)
34. Newby LK, Harrington RA, Bhapkar MV, Van de Werf F, Hochman JS, Granger CB, Simes RJ, Davis CG, Topol EJ, Califf RM, Moliterno DJ (2002) An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: Insights from PARAGON A. J Thromb Thrombolysis 14(1):33-42